Drug intelligence / Profile preview

Pregamix

Development stage: Unknown
Lead developer: Kaiser Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**Pregamix** is an oral fixed-dose capsule marketed by Kaiser Pharmaceuticals containing **pregabalin 75 mg** and **methylcobalamin 750 mcg**. It is used for management of neuropathic pain. Pregabalin binds the alpha-2/delta auxiliary subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release and pain signaling, while methylcobalamin is an active vitamin B12 cofactor used to support neuronal metabolism and repair. Kaiser Pharmaceuticals lists Pregamix Capsules among its products, and a pharmacy listing identifies the product composition as pregabalin 75 mg plus methylcobalamin 750 mcg. ([kaiserpharmaceuticals.com](https://kaiserpharmaceuticals.com/our-products.html))

Brand names: Pregamix

Targets

CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)

Beyond the preview

Go deeper on Pregamix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pregamix.

Explore the full profile